News – Page 295 – Selby Spine

ST. LOUIS, Sept. 26, 2016 /PRNewswire/ —ulrich medicalUSA, Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States, today announced the U.S. market release of uCerv titanium spinal implants as an adjunct to its current uCerv PEEK OPTIMA® Interbody System which is an existing product used for anterior cervical discectomy and fusion (ACDF) surgical procedures.

“Spinal implants made from solid titanium alloy can support bone growth at the fusion site by providing proven and reliable structural integrity,” said Ali A. Baaj, M.D., Assistant Professor of Neurological Surgery at Weill Cornell Medical College in New York. “I like the easy-to-use uCerv instrumentation which incorporates a slim designed inserter that allows for superior visualization and unimpeded work space at the surgical site.” Dr. Baaj went on to say, “This product line also features a beneficial large graft window which allows for the usage of maximum bone graft material and it is available in a wide variety of sizes.”

The uCerv titanium implants have a roughened-surface design with a trapezoidal shape and are available in parallel or lordotic configurations of various heights in small, medium and large footprints. In addition, these implants feature optimal teeth patterns on the superior and inferior surfaces to limit migration.

For more information, please visit www.ulrichmedicalusa.com.

About ulrich medical USA, Inc.
ulrich medical USA, Inc. is a privately-held subsidiary of ulrich medical®, an innovative medical technology company headquartered in Ulm, Germany which is celebrating 104 years in business in 2016.

Company Contact: e.laskey@ulrichmedicalusa.com

Photo – http://photos.prnewswire.com/prnh/20160913/407241

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ulrich-medical-usa-announces-product-line-extension-releases-ucerv-titanium-cervical-interbody-system-300329631.html

FORT LAUDERDALE, Fla. – Sept. 23, 2016

Stryker Hip Replacement Metal V 40 Femoral Heads Recall Alert
Stryker Hip Replacement Helpline is gearing up for a nationwide outreach to all people to alert them to the fact that Stryker has voluntarily recalled some of their metal V40 femoral heads used with hip implants. This affects the Exeter, Citation, Meridian, Reliance, Definition, Restoration, Accolade Rejuvenate and ABG 2 stems. The Helpline want to inform all Stryker Hip Replacement recipients that failure of these heads is caused by corrosion and metal debris at the junction between the metal head and neck. The clinical results for patients include pain, loss of mobility, ambulation problems and an inability to work. Poisoning of the soft tissue, muscle and bone are the cause. Revision surgeries are needed due to premature failures. Patients with V40 metal heads that suffer hip poisoning have substantial medical and legal needs.

This is a major undertaking to locate all patients with a Stryker Hip Replacement to be a part of the expected lawsuits for complications such as wear debris, metallosis, joint destruction, infection and need for additional revision surgeries.

The Stryker Hip Replacement Helpline is gearing up for what they feel is a second round of Stryker Hip Replacement lawsuits. “We expect a new wave of T.V. ads by lawyers. Patients will see lawyer ads on T.V. and they will have a lot of questions. They want to speak to someone they feel safe and comfortable with and they call us,” says the helpline medical social worker at 1 877 522-2123.

The outreach is a massive undertaking for the Stryker Hip Replacement Helpline. Their mission is clear and they are ready. They expect to be adding 5-10 new cities a week until they have the major cities in the U.S. covered. The helpline is seeking all people Implanted with a Stryker Exeter, Citation, Meridian, Reliance, Definition, Restoration, Accolade Rejuvenate and ABG 2 stems who are starting to have complications or whose physicians have received the recall letter from Stryker. If you have a Stryker hip replacement, we suggest you contact your physician to find out if they have received the letter and to confirm what type of hip replacement you have. Call the helpline immediately after that.

Stryker Hip Replacement Helpline Recall Alert Outreach Begins

The first round of Stryker V40 femoral heads recall Outreach is projected to reach the following cities:

New York, N.Y.,
Los Angeles, Calif.,
Chicago, Ill.,
Houston, Texas,
Philadelphia, Pa.,
Phoenix, Ariz.,
San Antonio, Texas,
San Diego, Calif.,
Dallas, Texas,
San Jose, Calif.,

Second Stryker Hip Replacement V40 femoral heads Outreach Campaign

Jacksonville, Fla.,
Indianapolis, Ind.,
San Francisco, Calif.,
Austin, Texas,
Columbus, Ohio,
Fort Worth, Texas,
Charlotte, N.C.,
Detroit, Mich.,
El Paso, Texas,
Memphis, Tenn.,

Third round Stryker Hip Replacement V40 femoral heads recall outreach alert

Baltimore, Md.,
Boston, Mass.,
Seattle, Wash.,
Washington, DC,
Nashville
Denver, Colo.,
Louisville,
Milwaukee, Wis.,
Portland, Ore.,
Las Vegas, Nev.,

Additional Lawsuits Outreach

Oklahoma City, Okla.,
Albuquerque, N.M.,
Tucson, Ariz.,
Fresno, Calif.,
Sacramento, Calif.,
Long Beach, Calif.,
Kansas City, Mo.,
Mesa, Ariz.,
Virginia Beach, Va.,
Atlanta, Ga.,
Colorado Springs, Colo.,
Omaha, Neb.,
Raleigh, N.C.,
Miami, Fla.,
Cleveland, Ohio,
Tulsa, Okla.,
Oakland, Calif,.
Minneapolis, Minn.,
Wichita, Kan.,
Arlington,

Stryker Hip Replacement Recall Alert

Stryker has voluntarily recalled some of their metal V40 femoral heads used with hip implants. Specifically, these metal heads are associated with wear debris, metallosis, joint destruction, infection and need for revision surgery. Stryker Hip Replacement Helpline has a dedicated number for assistance 1 877 522-2123 or contact us using the contact form of the website.

http://strykerhipreplacementhelpline.com/

Contact
Lisa Spitzer MSW
***@strykerhipreplacementhelpline.com

Broomfield, CO – September 26, 2016 – Zimmer Biomet Spine, Inc. today announced positive topline data on the Aspen MIS Fusion System and the Timberline Systems from three studies validating less invasive treatment methods for degenerative disc disease and spondylolisthesis. The studies will be presented as ePosters during the Congress of Neurological Surgeons Annual Meeting (CNS), September 24 to 28 in San Diego.

“Zimmer Biomet’s clinical data demonstrates the benefits of less-invasive spinal fusion techniques, at a time when the industry is continuing to improve minimally invasive treatment options for patients,” said Adam Johnson, Group President of Zimmer Biomet Spine, Dental, CMF and Thoracic. “We look forward to discussing the one-year outcomes of our randomized controlled trial, as well as executing more research in the future so we can continue to develop the evidence necessary to support excellent patient outcomes.”

Demonstrations of the Aspen MIS Fusion System and the Timberline Systems will be available at Zimmer Biomet Booth #429.

ePosters:

Interspinous Process Fixation versus Pedicle Screw Fixation in Circumferential Arthrodesis: Outcomes from a Prospective Randomized Multi-Center Trial(ePoster 1287)

Lead Investigator: Dr. Kee Kim; UC Davis Health System, Dept. of Neurosurgery

Product Focus: Aspen MIS Fusion System

Lateral Lumber Interbody Fusion with Integrated Lateral Modular Plate Fixation: Intraoperative and Follow-Up Outcomes (ePoster 1312)

Lead Investigator: Dr. Ryan DenHaese; AXIS Neurosurgery and Spine

Product Focus: Timberline MPF Lateral Fixation System; Aspen MIS Fusion System

Anterior Versus Lateral Circumferential Lumbar Arthrodesis: Outcomes from a Prospective Multi-Center Study (ePoster 1301)

Lead Investigator: Dr. Kee Kim; UC Davis Health System, Dept. of Neurosurgery

Product Focus: Timberline Lateral Fusion System; Aspen MIS Fusion System

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

CAESAREA, Israel–(BUSINESS WIRE)– Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a leading developer of innovative bone mounted surgical guidance systems, announced today that Sharon Levita, Chief Financial Officer, is scheduled to present an overview of the Company at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September 27, 2016 at 11:30 a.m. ET (6:30 p.m. IST). The conference will be held at the Sofitel Hotel in New York City.

A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website. To access the webcast, please use the following address http://wsw.com/webcast/ladenburg2/mzor or visit www.mazorrobotics.com and select Investor Relations.

In addition the Company announced that it will report third quarter system orders on Monday, October 10^th.

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160926005911/en/

Contacts

U.S. Contacts: EVC Group
Investors
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
Doug Sherk, 415-652-9100
dsherk@evcgroup.com
or
Media
David Schemelia, 646-201-5431
dave@evcgroup.com

Source: Mazor Robotics Ltd.

A Conversation with Gary Stevenson, Co-Founder and Managing Partner at MB Venture Partners, LLC

Let’s start by having you give a brief background on who you are, what MB Ventures is and why you started MNVC.

My name is Gary Stevenson and I am co-founder and managing partner of MB Venture Partners in Memphis. We started in 2001 and raised our first fund in 2002. In our first 15 years, we have focused a disproportionate amount of our investment capital on the musculoskeletal niche where we have domain expertise and relationships that have resulted in high-quality investment opportunities. Over the years, our start-ups have been acquired by Wright Medical, Medtronic, Smith & Nephew, and Zimmer Biomet.

One of our venture partners, with the help of the Memphis Bioworks Foundation, started in the MNVC in 2003, so this will be our 14th annual event. The goal then was to feature the relative strengths of Memphis in the musculoskeletal industry. MB Venture Partners has been Conference Host and the largest sponsor every year since then. Our goal is to bring together the 20-25 most exciting new start-ups so they can engage with investors (both venture capitalists and angels) and strategic partners (Medtronic, Smith & Nephew, Wright Medical, and may others).

MNVC being October 18-19^th, it falls right in the middle of the busy season for orthopedic industry meetings, yet many of us industry “junkies” consider MNVC to be a “Can’t Miss” meeting. Why do you think that is?

I appreciate the compliment – I do think MNVC is the “can’t miss” event of the year for musculoskeletal start-ups and the people who love them. We don’t aim to be the largest event of the year, but we do want to be the best. As one example, we give presenters plenty of time at the podium to tell their story – 30-minute time slots. This is less superficial than other events and allows the depth that industry insiders are looking for. I think insiders want more than a 6-minute or 10-minute presentation can give them and that’s one reason why we all come to the MNVC. That and the barbecue.

What kind of companies typically present at MNVC?

We strive for balance when we curate the presenter list. It’s by invitation only and we’re looking for a mix of spine and orthopedics. We’re also looking for a mix of early and later-stage opportunities. We have been told many times that the MNVC is the one place where start-ups like to “break stealth”, that moment in time when management thinks they’re ready to tell the industry more about what they’re up to. We’re flattered to hear that, obviously.

Tell our readers about the beneficiary of the meeting proceeds and your passion about giving back to your community.

As returning attendees already know, MB Venture Partners doesn’t host the MNVC with an eye towards making a profit. If we were, we would be selling presentation slots (they’re free) and we’d be dividing the hour into 6 10-minute slots or even worse, 10 6-minute slots. Also, we don’t hire an outside firm to manage the conference for us. Truth is, MB Venture Partners donates all of its time putting the event on every year and pays for the privilege – we’ve written the largest sponsorship check every year. We do all that because we’re trying to keep costs low. A portion of each year’s proceeds is donated each year to the Memphis Academy of Science and Engineering (“MASE”), Tennessee’s first charter school. MASE helps inner-city students achieve their dream of a job in the technology and medical device fields. MASE was founded by the Memphis Bioworks Foundation and it warms our heart to know that more than $120,000 has been donated from the MNVC to benefit the teachers and students of MASE.

Princeton, NJ and Or Akiva, Israel, September 26 — Regentis Biomaterials, a developer of hydrogels for tissue regeneration, announced it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to initiate a pivotal Phase III clinical study of GelrinC, a novel treatment for focal cartilage defects in the knee. This clinical study will be used to support a Premarket Approval Application (PMA) which will allow Regentis to market GelrinC in the U.S.

The cartilage repair market is the largest unmet need in orthopedic sports medicine today, and represents an estimated market opportunity of more than US $1 billion. Articular cartilage is the smooth, white tissue covering the ends of bones where they come together to form joints. Cartilage has limited ability to repair itself, which means that surgical intervention is often required. Focal defects typically occur as a result of trauma and are extremely painful to the patient. Microfracture, the standard of care procedure, provides only short-term relief to patients and often requires additional surgical intervention.

“Gaining IDE approval is a significant step forward for Regentis and brings us that much closer to helping US patients recover from damaged articular knee cartilage,” said Regentis President and CEO Alastair Clemow. “GelrinC has been shown to effectively regenerate high quality cartilage, a key challenge in treating these kinds of knee injuries. GelrinC has already demonstrated excellent clinical outcomes in our European study, and we look forward to substantiating these results in the U.S.”

The GelrinC procedure is easy and quick for surgeons to perform and can be carried out using a minimally invasive approach. It is administered as a liquid allowing it to fill any size and shape of defect, making it suitable for all lesion types. After a short exposure to ultra-violet light, GelrinC is converted into a solid implant completely filling in the lesion. The implant naturally degrades within 6-12 months and is gradually replaced with functional and durable cartilage.

“GelrinC is a potential game changer in the cartilage repair space, and can be an attractive and viable option for patients,” said Dr. Brian J. Cole, Associate Chairman and Professor within the Department of Orthopedics at Rush University Medical Center in Chicago. “GelrinC has promising clinical outcomes to date and the pre-clinical work is very supportive.”

This FDA trial will evaluate the safety and efficacy of GelrinC compared to the raw level data of a historical microfracture control arm. The study design overcomes the limitation of randomized control studies in this field, which is expected to result in faster patient enrollment and significantly reducing the time for product approval.

About Regentis Biomaterials

With offices in Or Akiva, Israel and Princeton, NJ, Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a biodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion – Israel Institute of Technology by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications. For more information, please visit www.regentis.co.il.
For media inquiries, please contact:

Josh Turner

Media Relations

Phone: 917-231-0550

josh@jtpublicrelations.com

Alastair Clemow, PhD

President & CEO

1-508-930-8865

CENTENNIAL, Colo., Sept. 23, 2016 /PRNewswire-USNewswire/ — AlloSource, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, will share early results of its fresh cartilage allograft, ProChondrix® Cartilage Restoration Matrix during the International Cartilage Repair Society’s (ICRS) 13^th World Congress in Sorrento-Naples, Italy. The Industry Satellite Lunch Symposia will take place on Monday,26 September 2016 from 13:00 to 13:30 in the Sala Nettuna Room.

Vishal Mehta, M.D., orthopedic surgeon from Fox Valley Orthopedics in Geneva, Illinois, will present early results of ProChondrix transplantation on isolated articular cartilage defects. Patients underwent treatment of an isolated, symptomatic articular cartilage surface lesion, which was treated with microfracture and placement of a ProChondrix graft. The 12-month review post-treatment demonstrated early success and no failures. In addition to Dr. Mehta, Laurie Goodrich, D.V.M, Ph. D., associate professor in equine surgery and lameness at Colorado State University, will share the findings of a 12-month horse study.

“Clinical information is an important piece of the puzzle when finding products to help heal my patients,” said Dr. Vishal Mehta, orthopedic surgeon. “I am excited by the promising early results of my first patients who received ProChondrix.”

AlloSource will also present several posters at ICRS. One will focus on Dr. Mehta’s 12-month clinical results, another highlights Dr. Goodrich’s equine study findings, both previously mentioned, and another poster shares results from an internal study on ProChondrix’s likeness to healthy adult cartilage. The internal study found ProChondrix, a fresh cartilage allograft, inherently matches the biomechanical and biochemical properties of normal hyaline cartilage found in a healthy adult, proving it is a viable solution to help restore articular cartilage surfaces, relieve patient symptoms and improve function.

For more information on ProChondrix and the recently launched Reimbursement Hotline dedicated to assisting customers and providing information on coding options, coverage access and reimbursement, please visit ProChondrix.org.

About AlloSource
AlloSource is one of the largest nonprofit cellular and tissue networks in the country, offering more than 200 types of precise cartilage, cellular, bone, skin and soft-tissue allografts to advance patient healing. For more than 20 years, AlloSource’s products have bridged the proven science of allografts with the advanced technology of cells, offering life-saving and life-enhancing possibilities in spine, sports medicine, foot and ankle, orthopedic, reconstructive, trauma and wound care procedures. As the world’s largest processor of cellular bone allografts, fresh cartilage tissue for joint repair and skin allografts to help heal severe burns, AlloSource delivers unparalleled expertise and service to its growing network of surgeons, partners, and the country’s most reputable organ procurement organizations. The company is accredited by the American Association of Tissue Banks and is headquartered in Centennial, CO. For more information, please visit allosource.org or our educational website,allograftpossibilities.org.

Media Contact
Megan Duggan
AlloSource
720. 382. 2766
mduggan@allosource.org

SOURCE AlloSource

Related Links

http://www.allosource.org

TINAVI Medical Technologies is a Beijing-based group specializing in innovative medical devices. The company is a provider of avant-garde surgical systems and operating theatre solutions. Its third generation intelligent orthopedic robot, the TiRobot(TM), is the only surgical robot in the world capable of performing surgery on all areas of the spine (cervical, thoracic, lumbar, and sacral vertebrae). The company has been listed on Beijing’s NEEQ Stock Market since November, 2015.

This agreement will, from 2016 onwards, enable TINAVI Medical Technologies to distribute SPINEWAY implant ranges that are registered in China.

In this context, before the end of 2016, SPINEWAY will propose a capital increase to its shareholders. The capital increase would be made by way of issuance of shares with stock subscription warrants attached (BSA) reserved entirely to TINAVI Medical Technologies, with shareholders pre emption rights waived, for an amount of 1.399.724.40 EUR (including share premium).

The transaction will involve the issue of 355,260 new shares at a price of 3.94 EUR each, giving TINAVI Medical Technologies 9.09% share of the capital and 5.04% of voting rights.

A stock subscription warrant will be attached to each of these newly issued shares, with 10 stock subscription warrants giving the right to subscribe to 11 additional new shares at a unit price of 4.09 EUR each, representing a total of 390,786 additional new ordinary shares, representing a further maximum subscription of 1,598,314.74 EUR (share premium included). These stock subscription warrants may be exercised from 1^st June to 15^thSeptember, 2017. After this second tranche, if the issue is taken up completely, TINAVI Medical Technologies’ stake will account for 17.36% of the capital and 10.59% of voting rights.

The agreement also provides that TINAVI Medical Technologies be granted a priority right on any future financial transaction SPINEWAY might initiate, as well as the right to maintain its shareholding at the same level as provided for in the aforementioned capital increase transactions.

The agreement furthermore provides the appointment of TINAVI Medical Technologies or one of its representative as an observer to the board of directors, as the case may be, the appointment of TINAVI Medical Technologies or one of its representative as director in the event of the whole of the second investment tranche being taken up.

TINAVI Medical Technologies’ subscription undertaking is subject to a certain number of usual conditions for such kind of transaction.

This operation enjoys the support of Messrs Le Roux and Laurito, key, long-standing shareholders of SPINEWAY, who hold together 87.03% of the company voting rights. They have committed to vote in favor of all the resolutions related to this transaction, which will be submitted to the next extraordinary shareholders’ meeting.

For SPINEWAY CEO Stéphane Le Roux, “This new agreement opens up new prospects for SPINEWAY. I’d like to thank Mr. Zhang Songgen, whose group will become a key shareholder, for the confidence shown in our company and our know-how. Our Chinese deployment will now revolve around a front-stage actor, recognized worldwide for its innovation in the orthopedics field.”

TINAVI CEO Mr. Zhang Songgen states, “We are delighted to announce a new strategic partnership between our company, TINAVI Medical Technologies, and SPINEWAY, which will bring new, additional therapies to the world of spinal surgery. By combining our expertise, we shall bring in innovations on a worldwide scale that will be decisive for surgeons specializing in problems and diseases of the vertebral column.”

Contacts :


Investor relations David Siegrist – CFO Tél : +33 (0)4 72 77 01 52 finance.dsg@spineway.com		Financial communications Jérôme Gacoin / Solène Kennis Tel : +33 (0)1 75 77 54 68 skennis@aelium.fr

SPINEWAY signs a partnership deal with TINAVI Medical Technologies
Sep 22, 2016

Los Angeles, CA (PRWEB) September 19, 2016

Dr. Daniel C. Allison, a board-certified orthopedic surgeon in Los Angeles specializing in orthopedic oncology, anterior hip replacement, and joint reconstruction, has announced that he is scheduled to perform the first bone anchored (osteointegrated) prosthesis surgery in Southern California. The patient is a former police officer with an above-the-knee amputation.

“We are very excited to be the first practice in Southern California to offer the surgery,” said Dr. Allison. “We make limb preservation a priority for our soft tissue and bone sarcoma patients, and are constantly working to bring the latest surgical innovation techniques to our joint replacement and hip arthroplasty treatments for both adult and pediatric patients.”

Traditional prosthetics use a ball and socket design. The socket is placed around the end of the affected limb, to which the prosthetic arm or leg is then attached. While this approach is highly effective in many cases, it requires enough surface area on the remaining limb to adequately attach the cap with the socket. It can also present issues with comfort and fit.

The Osseoanchored Prosthesis for the Rehabilitation of Amputees (OPRA), which has been approved by the FDA (Food and Drug Administration) for use in above the knee amputees, implants a titanium fixture directly into the bone. Once the fixture has integrated and healed, a rod is attached through the skin, which then connects to the prosthetic leg. The benefits of this approach include greater mobility, range of motion, and comfort. It also offers hope for amputees who are not good candidates for or have had limited success with traditional socket prosthetics. Using a titanium implant helps to mitigate the risk of rejection from the bone.

Learn about bone anchored prosthesis: http://www.DrAllison.org/Bone-Anchored-ProstethisOsteointegrated-OI-Prosthesis/

“With proper care and comprehensive physical therapy and rehabilitation, we are very optimistic that this approach will offer a significant improvement in quality of life for many adults, especially veterans and members of law enforcement like our patient, with above-the-knee amputations,” added Dr. Allison.

About Daniel C. Allison, MD, FACS.

Daniel C. Allison, MD, FACS, MBA, is board certified in orthopedic surgery with expertise in musculoskeletal oncology, joint reconstruction, and anterior hip replacement. He is Assistant Director of Orthopedic Oncology, Cedars-Sinai Sam Oschin Cancer Center. Dr. Allison is a fellow of the American College of Surgeons and the American Academy of Orthopedic Surgeons. As an orthopedic oncologist, Dr. Allison is a recognized leader in malignant problems of the musculoskeletal system, including soft tissue and primary sarcomas of the bone, invasive metastatic bone cancer, and invasive skin cancers of the back, pelvis, shoulder girdle, and extremities.

For more information about us, please visit http://www.DrAllison.org/

Daniel C. Allison, MD FACS
444 S San Vicente Blvd #603
Los Angeles, CA 90048
info(at)DrAllison(dot)org

September 22, 2016

BEDFORD, Mass. & NAPLES, Italy–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced four data presentations on HYALOFAST, a biodegradable HA-based scaffold, at the 13^th World Congress of the International Cartilage Repair Society (ICRS). The ICRS World Congress, which is being held in Sorrento, Naples, Italy during September 24-27, 2016, is the world’s largest gathering of scientists, clinicians and industry participants focused on clinical cartilage repair and basic cartilage research.

“We’re proud to showcase the results of four recent and important studies evaluating the clinical utility of our biodegradable scaffold, HYALOFAST, before an audience of world-renowned experts in the field of cartilage repair and regeneration. Collectively, the data reinforce the significant advantages HYALOFAST offers over invasive surgical interventions and traditional scaffolds, specifically in terms of ease of use, efficiency and positive treatment outcomes,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer, Anika Therapeutics. “In addition, at our booth this year, we’re excited to debut the HYALOFAST Virtual Simulator, a digital training tool exclusively designed to allow physicians to experience a guided simulation of the entire HYALOFAST procedure in virtual reality.”

HYALOFAST is a non-woven biodegradable hyaluronic acid-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects. HYALOFAST is commercially available in over 15 countries and has been used in more than 7,000 patients to date. HYALOFAST is pending regulatory submission in the United States and its ‘FastTRACK’ Phase III trial is currently enrolling patients across the U.S. and Europe.

HYALOFAST Data and Poster Presentations
Sunday, September 25, 2016

1. One-stage Cartilage Repair using Hyaluronic acid-based Scaffold and Mesenchymal Stem Cells (HA-BMAC) Compared to Microfracture: 5 Year FU (Authors: A. Gobbi, G. Whyte, B. Sadlik)
2. Arthroscopic Cartilage Repair using a Hyaluronic Acid-based Scaffold and Activated Bone Marrow-derived Mesenchymal Stem Cells (HA-BMAC) (Authors: G. Whyte, A. Gobbi, B. Sadlik)
3. Medium-term Outcomes of Cartilage Repair using Hyaluronic acid-based Scaffold with Multipotent Stem Cells in Patients Over 45 Years of Age (Authors: A. Gobbi, G. Whyte, M. Castro, B. Sadlik)

Monday, September 26, 2016

1. Hyaluronic acid-based scaffold versus bilayer collagen scaffold in patellofemoral chondral defect repair using dry arthroscopy(Authors: M. Puszkarz, B. Sadlik, A. Gobbi, M. Wiewiorski, B. Gaj, W. Klon, G. Whyte)

Company-Sponsored Symposia
Sunday, September 25, 2016

1. Hyalofast: One Step Cartilage Regeneration From Trauma To Early Degenerative Lesions
Moderators: Dr. Francesca Vannini (Rizzoli Institute – Bologna –Italy) and Dr. Boguslaw Sadlik (St. Luke Clinic – Bielsko-Biala –Poland)
Speakers: Dr. Brunella Grigolo (Rizzoli Institute – Bologna –Italy), Prof. Roberto Buda (Rizzoli Institute – Bologna –Italy), Prof. Alberto Gobbi (O.A.S.I. Bioresearch Foundation – Milan –Italy)

Conference Location: Hilton Sorrento Palace, Sorrento – Naples, Italy
Anika Booth: # 6

About ICRS
The ICRS (International Cartilage Repair Society) is the main forum for international collaboration in cartilaginous tissue research that brings together basic scientists, clinical researchers, physicians and members of industry, engaged or interested in the field of articular biology, its genetic basis and regenerative medicine. It provides continuing education and training to physicians and scientists with an active interest in the prevention and treatment of joint disease to improve patient care through regenerative medicine approaches.

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedics medicines company based in Bedford, Mass. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing clinically meaningful therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing and commercializing more than 20 products, in markets across the globe, based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio is comprised of marketed (ORTHOVISC^® and MONOVISC^®) and pipeline (CINGAL^® and HYALOFAST^® in the U.S.) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. For more information about Anika, please visit http://www.anikatherapeutics.com.

Forward-Looking Statements

The statements made in the third paragraph of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the enrollment of patients in the Hyalofast clinical trial and the U.S. regulatory submission associated with Hyalofast. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence and/or complete clinical trials of its products, including for Hyalofast, on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (x) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
or
For Media Inquiries:
Pure Communications
Susan Heins, 864-286-9597

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

ulrich medical USA® Announces Product Line Extension, Releases uCerv® Titanium Cervical Interbody System

Stryker Hip Replacement Helpline Recall Alert

Zimmer Biomet to Feature Clinical Data on the Aspen® MIS Fusion System and the Timberline® Systems during the Congress of Neurological Surgeons (CNS) Annual Meeting

Mazor Robotics to Present at the Ladenburg Thalmann Annual Healthcare Conference

Contacts

PROFILE – Musculoskeletal New Ventures Conference (MNVC)

Regentis Receives IDE Approval for Pivotal GelrinC Clinical Trial

International Cartilage Repair Society Symposia To Highlight Early Findings Of Prochondrix Cartilage Restoration Matrix

SPINEWAY SIGNS A PARTNERSHIP DEAL WITH TINAVI MEDICAL TECHNOLOGIES

Los Angeles Orthopedic Surgeon Scheduled to Perform First Bone Anchored Prosthesis Surgery in Southern California

Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society

Contacts

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS